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The selection of the crystalline phases in a form of molecular cocrystals has become scientific 
challenge at the early stage of drug development of pharmaceutical formulations and in the late 
stage of synthesis and isolation of Active Pharmaceutical Ingredients (APIs) in desirable defined 
crystalline forms. Optimal crystal form of API interactively interrelates and impacts its aqueous 
solubility and dissolution rate that are benchmark for drug delivery and absorption determining 
the extent of its bioavailability and pharmacokinetics profile. Hence, determining the crystal 
structure and revealing the crystal packing forces and geometry of the API impact upon its 
physicochemical properties what it is a threshold for controlling the performance of the API. The 
range of crystal forms in which molecular cocrystals of APIs may exist are advantageous 
comparing to its polymorphs, salts, solvates and hydrates due to the vast number of potential 
coformers which extend the limited counterions for salt formation implying the existence of more 
complex intermolecular interactions based on different H-bonding patterns with API that lead to 
conformational changes and flexibility for crystal packing in process of cocrystallization.  
Selected case-studies of cocrystallization screening reveals determined crystal structures of 
pharmaceutical cocrystals composed of APIs that belong to different pharmacotherapy and 
functional group classes, respectively. The case study underlines the crystal growth and the 
method of preparation for “drug-drug” type of pharmaceutical cocrystals wherein two different 
APIs cocrystallized in single crystal cell, and that represent new paradigm for approaching in 
development of the “fixed-doses” or “combo” pharmaceutical formulations. Preliminary results of 
the Structure-Activity Relationship study on the cocrystals composed of metformin with 
dichloroacetic acid indicates dual and complementary pharmacological activities of the two 
selected drug models for cocrystallization.  
 
